Balyasny Asset Management’s Fulgent Genetics FLGT Stock Holding History

Balyasny Asset Management’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13M	Buy	+55,078	New	+$934K	﹤0.01%	2140
2025 Q3	–	Sell	-16,097	Closed	-$320K	–	3077
2025 Q2	$320K	Sell	16,097 -53,329	-77%	-$1.04M	﹤0.01%	2464
2025 Q1	$1.17M	Buy	69,426 +43,113	+164%	+$734K	﹤0.01%	1927
2024 Q4	$486K	Buy	+26,313	New	+$514K	﹤0.01%	2202
2024 Q2	–	Sell	-10,994	Closed	-$239K	–	2736
2024 Q1	$239K	Buy	+10,994	New	+$273K	﹤0.01%	2342
2023 Q3	–	Sell	-8,609	Closed	-$319K	–	2404
2023 Q2	$319K	Buy	+8,609	New	+$300K	﹤0.01%	1974
2023 Q1	–	Sell	-13,700	Closed	-$408K	–	2820
2022 Q4	$408K	Sell	13,700 -20,333	-60%	-$728K	﹤0.01%	1907
2022 Q3	$1.3M	Buy	34,033 +1,331	+4%	+$66.7K	﹤0.01%	1694
2022 Q2	$1.78M	Buy	+32,702	New	+$1.8M	0.01%	1475
2021 Q4	–	Sell	-2,962	Closed	-$266K	–	2356
2021 Q3	$266K	Buy	+2,962	New	+$269K	﹤0.01%	1612

Other funds holding FLGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Balyasny Asset Management's FLGT Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Fulgent Genetics (FLGT) in Q2 2026: 55,078 shares worth $1.13M. The stake represents ﹤0.01% of the portfolio and ranks #2140 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in FLGT as recently as Q2 2025.

Balyasny Asset Management first reported a position in FLGT in Q3 2021 and has held it in 10 quarters since. The position peaked at $1.78M in Q2 2022. 141 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

Balyasny Asset Management held 55,078 shares of Fulgent Genetics worth $1.13M as of Q2 2026.
Fulgent Genetics was a new Balyasny Asset Management position in Q2 2026.
Fulgent Genetics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2140 holding.
Balyasny Asset Management first reported a position in Fulgent Genetics in Q3 2021 and has held it in 10 quarters since.
Balyasny Asset Management's Fulgent Genetics position peaked at $1.78M in Q2 2022.
141 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.